Spyre Therapeutics, Inc. SYRE Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s additional paid-in capital?
- Spyre Therapeutics, Inc. (SYRE) reported additional paid-in capital of $1.71B in Q1 2026.
- How has Spyre Therapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Spyre Therapeutics, Inc.'s additional paid-in capital increased by 27.5% year-over-year, from $1.34B to $1.71B.
- What is the long-term trend for Spyre Therapeutics, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s additional paid-in capital has grown at a 32.3% compound annual growth rate (CAGR), from $415.82M to $1.69B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.